ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33 CLINICAL TRIAL NOT ALLOWED)

ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33 CLINICAL TRIAL NOT ALLOWED)

Up to $300,000 per year (in direct costs). - Friday, October 03, 2025

National Institute of Health
The National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research.

Funding Opportunity

Visit the funding page (members only, sign in): ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33 CLINICAL TRIAL NOT ALLOWED)

Sign in or register for free to read the full details and apply

Sign in Create a free account

Share:

All funding opportunities